Document:

c49643_ex10-22part1.htm -- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing

Exhibit 10.22

CONFIDENTIAL TREATMENT REQUEST 

[ * ] indicates information that has been omitted pursuant to a

confidential treatment request and this information 

has been filed under separate cover with the Commission 

Amendment to Research and Licensing Agreement 

This Amendment to the Research and Licensing Agreement
(the “Amendment”)
is effective as of December 23rd,_,
2007 (“Effective Date"),
by and among GammaCan Ltd. (“GammaCan”)
and Tel Ha’Shomer-Medical Research Infrastructure and Services LTD. (“THM”).
Each of THM and GammaCan shall be referred to as a
"Party” or
together as the "Parties”. 

     WHEREAS, GammaCan and THM have entered into a Research and Licensing Agreement, dated December 13, 2005 and acknowledged by Dr. Miri Blank
(the “Original Agreement”); 

     WHEREAS, the Parties hereto wish to amend certain provisions of the Original Agreement for the purpose of including the VitiGamTM Product, which is solely and exclusively owned by GammaCan, in the Research Project (as such term is defined in the Original Agreement) in order for THM to receive royalties from Net Sales and
other revenues (as set forth below).

     All capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the Original Agreement;

NOW, THEREFORE, in consideration of the mutual promises, covenants, conditions, representations and warranties set forth herein, and intending to be legally bound hereby, the parties
agree as follows: 

	
1  	
.   	   	
Section 1.2A is hereby added to the Original Agreement as follows:   
	   
	   
	                           	                           	                           	
    1.2A. “GammaCan Rights”:
        shall mean all conceptions, intellectual property,         inventions, data, information, materials, and rights thereof to: (i) GammaCan's         VitiGamTM Product and to the technology and know-how relating to anti-angiogenesis,         (ii) the patents and patent applications listed in Exhibit B hereto, acquired by         GammaCan from ARP BioMed Ltd. (“ARP”); (iii)
        the conceptions, know-how and ideas         derived from the manuscripts listed in Exhibit C acquired by GammaCan from ARP;         (iv) the conceptions, know-how and ideas derived from the presentation attached as         Exhibit D acquired by GammaCan from ARP; (v) all conceptions, ideas, inventions,         technologies, know-how and scientific and technical information derived from (i), (ii),         (iii) or (iv) above; and/or (vi) any patents or patent applications claiming and/or         disclosing subject matter of (i), (ii), (iii) and/or (iv) herein (collectively, the         "GammaCan Rights"), including

any current or
    prior Research Projects and any and all         research activities conducted by THM. .   

	   
	
2  	
.   	   	
    Section 1.4 is hereby deleted in its entirety, and replaced by new Section 1.4 as follows:   

1

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant
to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.  

	       	       	       	
1.4 “Licensed Product” shall mean any product developed in connection with and/or based on the Subject Technology and covered by a Valid Claim of a Patent, and/or based on the GammaCan Rights.   
	   
	
3    	
.     	     	
    Section 1.7 is hereby amended
    as follows: “Appendix 2” shall be renumbered as         “Appendix 1”.   

	 	 	 	 
	
4  	
.   	   	
Section 1.9 is hereby deleted in its entirety and a
new Section 1.9 shall be added as follows:   
	   	   	   	   
	               	               	               	
    “Research Period” shall
    mean a two (2) year term beginning on January 1st 2007 and         ending on December 31st 2008, and any extension thereof on a going forward calendar         year basis to which THM and GammaCan shall mutually agree in writing. If at any time         the Principal Investigator has reason(s) to believe work will not be completed within the         Research Period, the Principal Investigator will advise GammaCan of the reason(s) and         length of time required to complete the Research Project and the Research Period shall         be extended accordingly.   

	 	 	 	 
	
5  	
.   	   	
Section 1.10 is hereby amended as follows: “Appendix
1” shall be renumbered as “Appendix
2”.    
	 	 	 	 
	
6          	
.           	           	
    Section 1.12, the following
        words at the end of Section 1.12 are deleted “In addition,         not included in such sublicense consideration
        is equity investments” and replaced with         “In addition, not included in such sublicense
    consideration are proceeds of fundraising         including equity investments, debt, convertible debt, warrants, and any other financial         instruments."   

	 	 	 	 
	
7  	
.   	   	
Section 2.1 is hereby deleted in its entirety and a
new Section 2.1 shall be added as follows:    
	   	   	   	 
	                           	                           	                           	
    The Research Project as set forth in Appendix 2, shall be conducted by and under the direction of the Principal Investigator. THM shall provide personnel, facilities, and resources as required, and in accordance with the Research Project, to accomplish the work necessary to complete the Research Project. The Principal Investigator will be responsible for the execution and implementation of the Research Project in accordance with all applicable policies of the Hospital and all applicable Israeli laws and regulations. The Parties have agreed to the Research Project as set forth in Appendix 2. The Parties agree that sixty (60) days prior to the end of the Research Period both Parties shall have mutually negotiated in good faith and agreed to the continuance of the Research Project as set forth in a future amended appendix. The Parties agree that within three (3) weeks from the Effective Da
te of this Amendment, the Parties shall have mutually negotiated in good faith and agreed to the Research Project which shall be attached as Appendix 2 of the Original Agreement.   

	   
	   
	
8  	
.   	   	
Section 3.4 is hereby deleted in its entirety, and replaced by new Section 3.4 as follows   
	   
	 	       	       	
3.4 Sublicense
Fees: In the event that GammaCan or its
Affiliates grants a Sublicense to a 
Sublicensee in a given jurisdiction, GammaCan shall
pay sublicense payments to THM 
as follows:   

2

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant
to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.  

	             	             	
i)   	 	
    An amount equal to seven and
        one half percent (7.5%) of Sublicense Fees  actually received from such Sublicensee up to Six Million Six
Hundred Sixty Seven Thousand U.S dollars
    (US$6,666,667); and   

    
    
	 	 	   	 	 
	 	 	
ii)   	 	An
        amount equal to eight percent (8.0%) of Sublicense Fees actually received from such Sublicensee for
        all amounts above Six Million Six Hundred Sixty Seven Thousand U.S dollars
    (US$6,666,667).  

	   	 	 	 	 
	
9  	
.   	A new Section 3.5 shall be
    added as follows: 
	   	 	 	 	 
	                           	 	3.5 Warrants: Upon
    the execution and delivery hereof, GammaCan International, Inc.  shall
      execute and deliver to THM a warrant, substantially in the form of Exhibit
        A,  attached
          hereto, exercisable for an aggregate of 500,000 shares of common stock
          of  GammaCan International, Inc.
            on the terms, and subject to the conditions, set forth  therein.
              Within 30 days following the acceptance by the U.S. Food and Drug  Administration
                of each new Investigational New Drug (“IND”) application
                that arises  from, and is
                  the direct result of work described in, a current or prior Research
                  Project  pursuant to the
                    Research and Licensing Agreement, dated December 13, 2005, as  amended
                      by this Amendment thereto, excluding any INDs pertaining to VitiGamTM,  GammaCan
                        International, Inc. will issue to THM a warrant, substantially
                        in the form  of Exhibit
                          A, attached
                            hereto, to acquire an aggregate of 250,000 shares of
                            common  stock
                              of GammaCan International, Inc., the exercise price
                              of which shall be the closing  price
                                at the date of the issuance thereof. [Comment: Exhibit
                                A is a standard warrant.  The
                                  price is fair market value on the date of the Agreement.
    There are no variables]  

	   	 	 	 	 
	
10.                              	
                               	Section 4 is hereby deleted
    in its entirety and replaced by new Sections 4.1 and 4.2 that shall be added as follows:  

    

    4.1 Research Funding: During
    the first year of the Research Period, GammaCan shall pay
        THM the amount of fifty thousand U.S. dollars (US$50,000) + V.A.T
    to be paid for research performed by THM
    pursuant to the Research Project and the terms of this Agreement. During the second
    year of the Research Period, GammaCan shall pay THM the
        amount of four hundred and fifty thousand U.S. dollars (US$450,000)
    + V.A.T to be paid in equal quarterly installments.
    The above of which is as a result of the delay in the execution of this Amendment.
    Payments shall be made in Israeli currency according to the prevailing representative
    rate of exchange on the date of payment. The projected budget made under this Section
    shall be set forth in Appendix 1, as amended from time to time under his Agreement.
    The Parties agree that within three (3) weeks from the Effective Date of this Amendment,
    the Parties shall have mutually negotiated in good faith and agreed to the Research
    Funds which shall be attached as Appendix 1 of the Original Agreement.  

	   	 	 	 	 
	           	           	4.2 Financial Records: THM
    shall keep full and correct books of account, enabling the  Project Funds to be calculated
      and monitored separately. GammaCan or its authorized  representatives may, on a
        quarterly basis, upon written notice to THM, examine and  monitor any report, records
          and information in THM's or the Research Entity's book of  accounts relating to the Project
    Funds and performance of this Agreement, in order to  

3

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant
to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.  

	   	   	
monitor the use of the Project Funds, and if they are
not being used, adjust the amount of the Project
Funds.   
	   
	
11  	
.   	
In Section 7.3 the following sentence is hereby added prior to the first line:   
	   
	         	         	
    THM, acting as the trustee of the Hospital and/or the
      Fund, is and shall be the sole owner of any and all rights, title and interest
      in and to the Subject Technology and/or in and to any patents resulting from
      or arising under current or prior Research Projects and any and all related research
    activities conducted by THM.

	   
	   
	
12  	
.   	
A new Section 13.1 shall be added as follows:   
	   
	                     	                     	
    Further, THM represents and warrants that they have no rights or standing to pursue any causes of actions, remedies, injunctions, or any other relief, including but not limited to actions in law or equity, or any arbitration or mediation pertaining to the GammaCan Rights, and that THM hereby waives and releases GammaCan, ARP, their present, former and future shareholders, subsidiaries, directors, officers, employees, consultants, advisors, affiliates, agents and other representatives, and their respective successors and assignees, from all demands, actions, claims and liabilities whatsoever related, directly or indirectly, in whole or in part, to the GammaCan Rights. Nothing in this Section 13.1, shall preclude either Party from taking action against the other Party for breaches of any other terms and conditions of this Agreement.

	   
	
13  	
.   	
A new Section 1.23 shall be added as follows:   
	 	 	 	 
	     	     	
    1.23 “Royalty Term” shall
    mean the period commencing on the Effective Date and         ending at the later of either: (i) 20 years; or (ii) upon the last to expire of the Patents.   

	 	 	 	 
	
14	
.	
    Throughout the Original Agreement,
        the term “Licensing Term” is hereby replaced with the term “Royalty Term”, and the term "Principal Investigators” is
    hereby replaced with the term “Principal Investigator”.   

	 	 	 	 
	
15	
.	
    Except for the changes and/or
        additions stated herein, all the other terms of the Original Agreement
        shall remain valid and bind the parties without any change. In the case
        of a contradiction between the provisions of this Amendment and the provisions
        of the Original Agreement, the provisions of this Amendment shall prevail.
        Without limiting the generality of the foregoing, the term “Agreement” as
    used in the Original Agreement shall be deemed to be the Agreement as amended
        by this Amendment.

[The remainder of this page is left blank intentionally] 

4

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant
to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.  

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives. 

	
GammaCan Ltd.   	   	
Tel Ha’Shomer -Medical Research   
	   	   	
Infrastructure and Services LTD.   
	
By:   	   	
By:   
	
Name:   	   	
Name:   
	
Date:   	   	
Date:   
	   
	   
	   
	   
	
I confirm and agree:   	   	   
	   
	   
	
Dr. Miri Blank   	   	   
	   
	 	 	 
	 	 	 
	
Date:   	   	   

5

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant
to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.  

Exhibit A

NEITHER THE SECURITIES REPRESENTED HEREBY NOR THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD, PLEDGED, ASSIGNED, OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT
AND ANY APPLICABLE STATE SECURITIES LAWS, OR (2) THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF THIS WARRANT OR SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT THIS WARRANT OR SUCH SECURITIES,
AS APPLICABLE, MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED, OR OTHERWISE TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR APPLICABLE STATE SECURITIES LAWS. 

THE TRANSFER OF THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE HEREOF IS RESTRICTED AS DESCRIBED HEREIN. 

GAMMACAN INTERNATIONAL, INC. 

Warrants for the Purchase of 

Shares
of Common Stock, Par Value $0.0001 Per Share 

No.  

     THIS CERTIFIES that, for consideration, the receipt and sufficiency of which are hereby acknowledged, and other value received TEL
HA’SHOMER MEDICAL HEALTH INFRASTRUCTURE AND SERVICES LTD. (the “Holder”) is entitled to subscribe for, and purchase from, GAMMACAN INTERNATIONAL, INC., a Delaware corporation (the “Company”), upon the terms and conditions set forth herein, at any time or from
time to time on or after January 1, 2008 (the “Effective Time”) until 5:00 P.M. New York City local time on the fifth anniversary of the Effective Time (the “Exercise Period”), an aggregate of FIVE HUNDRED THOUSAND (500,000) shares of common stock, par value $0.0001 per share (the
“Common Stock”) of the Company.  This Warrant is initially exercisable at a price per share equal to $_________ [CLOSING PRICE ON THE EXECUTION DATE], subject to
adjustment as provided  

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange
Act of 1934, as amended. 

- 1 - 

herein; provided, however, that
upon the occurrence of any of the events specified in Section 8 hereof,
the rights granted by this Warrant, including the exercise price and the number
of shares of Common Stock to be received upon such exercise, shall be adjusted
as therein specified. The term “Exercise Price” shall
mean, depending on the context, the initial exercise price (as set forth above)
or the adjusted exercise price per share.

     As used herein, the term “this Warrant” shall mean and include this Warrant and any Warrant or Warrants hereafter issued as a
consequence of the exercise or transfer of this Warrant in whole or in part.  Each share of Common Stock issuable upon the exercise hereof shall be hereinafter referred to as a “Warrant Share”.  The Warrant Shares shall be subject to the restrictions on resale set forth in Section 23 hereof, as well as those imposed by applicable law. 

     1. (a) Subject to the terms of this Warrant, this Warrant may be exercised at any time in whole and from time to time in part, at the option of the Holder, on or after the Effective Time and on or prior to the end of the Exercise
Period. This Warrant shall initially be exercisable in whole or in part for an aggregate of 500,000 fully paid and nonassessable shares of Common Stock for an exercise price per share equal to the Exercise Price, by delivery to the Company at its
office at Kiryat Ono Mall, Azorim Center A, 39 Jerusalem Street, 55423 Kiryat Ono, Israel, or at such other place as is designated in writing by the Company, of: 

     (i) a completed Election to Purchase, in the form set forth in Exhibit I, executed by the Holder exercising all or part of the purchase
rights represented by this Warrant; 

      (ii) this Warrant; 

     (iii) if this Warrant is not registered in the name of the initial registered Holder, an assignment in the form set forth in Exhibit II
hereto evidencing the assignment of this Warrant to the current Holder; and 

     (iv) payment of an amount equal to the product of the Exercise Price multiplied by the number of shares of Common Stock being purchased upon such exercise in the form of, at the Holder’s option,
(A) a certified or bank cashier’s check payable to the Company, or (B) a wire transfer of funds to an account designated by the Company. 

     (b) This Warrant shall vest in its entirety and shall become exercisable at the close of business on December 31, 2008 (the “Vesting Date”). In the event that
the Research and Licensing Agreement, dated December 13, 2005, between the Company and Tel Ha’Shomer Medical Health Infrastructure and Services Ltd., as thereafter amended, shall terminate, prior to the Vesting Date, this Warrant shall
terminate and shall thereafter

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange
Act of 1934, as amended. 

- 2 - 

be of no further force or effect.

     (c) Upon the exercise of this Warrant, the Company shall issue and cause promptly to be delivered upon such exercise to, or upon the written order of, the Holder and in such name or names as the
Holder may designate, a certificate or certificates for the number of full Warrant Shares to which such Holder shall be entitled, together with cash in lieu of any fraction of a Warrant Share otherwise issuable upon such exercise. Such certificate
or certificates shall be deemed to have been issued, and any person so designated to be the person or persons entitled to receive the Warrant Shares issuable upon exercise of this Warrant shall be deemed to have become a holder of record of such
Warrant Shares for all purposes, as of the close of business on the date of the surrender of this Warrant and full payment of the Exercise Price.

      2. Upon each exercise of the Holder’s rights to purchase Warrant Shares, the Holder shall be deemed to be the holder of record of the Warrant Shares, notwithstanding that the transfer books of the Company shall then be
closed or certificates representing the Warrant Shares with respect to which this Warrant was exercised shall not then have been actually delivered to the Holder. As soon as practicable after each such exercise of this Warrant, the Company shall
issue and deliver to the Holder a certificate or certificates representing the Warrant Shares issuable upon such exercise, registered in the name of the Holder or its designee. If this Warrant should be exercised in part only, the Company shall,
upon surrender of this Warrant for cancellation, execute and deliver a Warrant evidencing the right of the Holder to purchase the balance of the aggregate number of Warrant Shares purchasable hereunder as to which this Warrant has not been exercised
or assigned. 

     3. Any Warrants issued upon the transfer or exercise in part of this Warrant shall be numbered and shall be registered in a warrant register (the “Warrant
Register”) as they are issued. The Company shall be entitled to treat the registered holder of any Warrant on the Warrant Register as the owner in fact thereof for all purposes, and shall not be bound to recognize
any equitable or other claim to, or interest in, such Warrant on the part of any other person, and shall not be liable for any registration of transfer of Warrants which are registered or to be registered in the name of a fiduciary or the nominee of
a fiduciary unless made with the actual knowledge that a fiduciary or nominee is committing a breach of trust in requesting such registration or transfer, or with the knowledge of such facts that its participation therein amounts to bad faith. This
Warrant shall be transferable on the books of the Company only upon delivery thereof duly endorsed by the Holder or by his duly authorized attorney or representative, or accompanied by proper evidence of succession, assignment, or authority to
transfer. In all cases of transfer by an attorney, executor, administrator, guardian, or other legal representative, duly authenticated evidence of his, her, or its authority shall be produced. Upon any registration of transfer, the Company shall
deliver a new Warrant or Warrants to the person entitled thereto. This Warrant may be exchanged, at the option of the Holder thereof, for another Warrant, or other Warrants of different denominations, of like tenor and representing in the aggregate
the right to purchase a like number of Warrant Shares (or 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange
Act of 1934, as amended. 

- 3 - 

portions thereof), upon surrender to the Company or its duly authorized agent. Notwithstanding the foregoing, the Company shall have no obligation to cause Warrants to be transferred on its
books to any person if, in the opinion of counsel to the Company, such transfer does not comply with the provisions of the Securities Act of 1933, as amended (the “Securities Act”), and the rules and regulations thereunder. 

      4. The Company shall pay all federal and state taxes (other than taxes on income of the Holder), documentary taxes, stamp taxes, if any, and other governmental charges that may be imposed upon the issuance or delivery of this
Warrant or upon the issuance or delivery of Warrant Shares upon the exercise of this Warrant, provided, however, that the Company
shall not be required to pay any taxes payable in connection with any transfer involved in the issuance or delivery of any Warrants or Warrant Shares in a name other than that of the Holder in respect of which such Warrant Shares are issued. The
Company may refuse to deliver the certificates representing the Warrant Shares being issued in a name other than the Holder’s name until the Company receives a sum sufficient to pay any tax that will be due because such shares are to be issued
in a name other than the Holder’s name. 

      5. (a)  The Company shall at all times reserve and keep available out of its authorized and unissued Common Stock, solely for the purpose of providing for the exercise of the Warrants, such number of shares of Common Stock as
shall, from time to time, be sufficient therefor. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this
Warrant, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue), without
any personal liability attaching to the ownership thereof and will not be issued in violation of any preemptive or similar rights of stockholders. The Company further covenants that its issuance of this Warrant shall constitute full authority to its
officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the trading market upon which the Common Stock may be listed. 

      (b) The transfer agent for the Common Stock and every subsequent transfer agent for any of the Company’s securities issuable upon the exercise of this Warrant shall be irrevocably authorized and directed at all times to
reserve such number of authorized securities as shall be required for such purpose. The Company shall keep a copy of this Warrant on file with the transfer agent for the Common Stock and with every subsequent transfer agent for shares of the
Company’s securities issuable upon the exercise of this Warrant. The Company shall supply

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange
Act of 1934, as amended. 

- 4 - 

such transfer agent with duly executed certificates representing the Common Stock or other securities for such purposes. 

     (c) The Company shall not by any action including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant; but will at all times in good faith assist in the carrying out of
all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of the Holder against impairment.  Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any
shares of Common Stock receivable upon the exercise of this Warrant above the amount payable therefor upon such exercise immediately prior to such increase in par value, and (b) take all such action as may be necessary or appropriate in order that
the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant. 

     6. The Company will (i) obtain and keep effective any and all permits, consents and approvals of Federal or state governmental agencies and authorities and make all filings under Federal and state
securities laws, that are required in connection with the issuance and delivery of this Warrant, the exercise of this Warrant, and the issuance and delivery of the Warrant Shares issued upon exercise of this Warrant, and (ii) have the Warrant
Shares, upon their issuance, listed on each securities exchange on which the Common Stock (or any other securities included in Warrant Shares) are then listed. 

     7. If the Company purchases or otherwise acquires this Warrant, the Company shall cancel this Warrant, and any Warrant surrendered for
exchange, substitution, transfer or exercise in whole or in part. 

     8. The Exercise Price for the Warrants in effect from time to time, and the number of Warrant Shares issuable upon exercise of the Warrants, shall be subject to adjustment as follows:

      (a) If the Company, at any time while this Warrant is outstanding: (A) pays a stock dividend or otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company pursuant to this Warrant), (B) subdivides outstanding shares of Common Stock into a larger number of shares, (C)
combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (D) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the
Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of
shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section 8(a) shall become effective immediately after the record 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange
Act of 1934, as amended. 

- 5 - 

date for the determination of stockholders entitled to receive such dividend or
distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. 

     (b) When any adjustment is required to be made in the Exercise Price pursuant to subsection 8(a), the number of Warrant Shares purchasable upon the exercise of this Warrant shall be changed to the number determined by dividing (i) an amount equal to product of the number of shares issuable upon the exercise of this Warrant immediately prior to such adjustment multiplied by the Exercise Price in effect
immediately prior to such adjustment, by (ii) the Exercise Price in effect immediately after such adjustment. 

      (c) Upon the occurrence of each adjustment or readjustment of the Exercise Price pursuant to this Section 8, the Company at its expense shall, as promptly as reasonably practicable but in any event not later than fifteen (15)
days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and furnish to the Holder a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property
for which this Warrant shall be exercisable and the Exercise Price) and showing in detail the facts upon which such adjustment or readjustment is based. The Company shall, as promptly as reasonably practicable after the written request at any time
of the Holder (but in any event not later than 15 days thereafter), furnish or cause to be furnished to the Holder a certificate setting forth (i) the Exercise Price then in effect and (ii) the number and class or series of Warrant Shares and the
amount, if any, of other securities, cash or property which then would be received upon the exercise of this Warrant. 

      (d) All calculations under this Section 8 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.

      (e) The Company shall not be required upon the exercise of this Warrant to issue any fractional shares, but shall pay the value thereof to the Holder in cash on the basis of the Fair Market Value per Warrant Share (as hereinafter
defined). “Fair Market Value” of a security shall mean, on any given day, the average of the closing prices of such security’s sales on all securities exchanges on which such
security may at the time be listed on such day, or, if there has been no sales on any such exchange on such day, the average of the highest bid and lowest ask prices on all such exchanges at the end of such day, or, if on such day such security is
not so listed, the average of the representative bid and ask prices quoted on the over-the-counter bulletin board (the “OTCBB”) as of 4:00 P.M., New York time, or, if on such day
such security is not quoted on the OTCBB, the average of the highest bid and lowest ask prices on such day in the domestic over-the-counter market as reported by the PinkSheet, LLC, or any similar successor organization. If at any time such security
is not listed on any securities exchange or quoted on the OTCBB or the over-the-counter market, the “Market Price” shall be as determined by the Board of Directors in good faith, absent manifest error. 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange
Act of 1934, as amended. 

- 6 - 

     9. Unless registered, the Warrant Shares issued on exercise of the Warrants shall be subject to a stop transfer order and the certificate or certificates representing the Warrant Shares shall bear the
following legend: 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE
SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD, PLEDGED, ASSIGNED, OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR (2) THE COMPANY RECEIVES AN OPINION
OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED, OR OTHERWISE TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR APPLICABLE STATE SECURITIES LAWS. 

     10. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new
Warrant or stock certificate of like date, tenor and denomination , in lieu of such Warrant or stock certificate. 

     11. (a) The Holder of any Warrant shall not have, solely on account of such status, any rights of a stockholder of the Company, either at law or in equity, or to any notice of meetings of stockholders
or of any other proceedings of the Company, except as provided in this Warrant. 

           (b) No provision hereof, in the absence of affirmative action by Holder to Warrant Shares, and no enumeration herein of the rights or privileges of Holder hereof, shall give rise to any liability of
such Holder for the purchase price of any Common Stock or as a stockholder of Company, whether such liability is asserted by Company or by creditors of Company. 

     12. Promptly upon the appointment of any subsequent transfer agent of the Common Stock, or any other securities issuable upon the exercise of this Warrant, the Company will deliver to the Holder a
statement setting forth the name and address of such subsequent transfer agent. 

     13. All notices and other communications provided for or permitted hereunder shall be in writing and shall be deemed given (i) when made, if made by hand delivery, (ii) upon 

- 7 - 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange
Act of 1934, as amended. 

confirmation, if made by
telecopier, or (iii) one business day after being deposited with a reputable next-day courier, postage prepaid, to the parties as follows: 

if to the Company:

GammaCan International, Inc.

Kiryat Ono Mall

Azorim Center A

39 Jerusalem Street

55423 Kiryat Ono, Israel

if to the Holder:

As set forth in the Warrant Register of the Company. 

           The Company or the Holder by notice to the other party may designate additional or different addresses as shall be furnished in writing by such party.  Any notice or communication mailed to the Holder
shall be mailed by first class mail or other equivalent means at such Holder’s address and shall be sufficiently given to such Holder if so mailed within the time prescribed. 

     14. The Company and the Holder may from time to time supplement, modify or amend this Warrant. 

     15. All the covenants and provisions of this Warrant by or for the benefit of the Company or the Holder shall be binding upon and shall inure to the benefit of their respective permitted successors
and assigns hereunder. 

     16. The Company shall not merge or consolidate with or into any other entity unless the entity resulting from such merger or consolidation (if not the Company) shall expressly assume, by supplemental
agreement satisfactory in form to the Holder and executed and delivered to the Holder, the due and punctual performance and observance of each and every covenant and condition of this Warrant to be performed and observed by the Company. 

     17.  The validity, interpretation and performance of this warrant shall be governed by the laws of the State of New York, as applied to
contracts made and performed within the state of New York, without regard to principles of conflicts of law. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York and the United States
District Court for the Southern District of New York, in each case sitting in the Borough of Manhattan, City of New York, for the purpose of any suit, action, proceeding or judgment relating to or arising out of this letter agreement. Service of
process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Warrant. Each of the parties 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange
Act of 1934, as amended. 

- 8 - 

hereto irrevocably
consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought
in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.

     18. The provisions hereof have been and are made solely for the benefit of the Company and the Holder, and their respective successors and assigns, and no other person shall acquire or have any right
hereunder or by virtue hereof. 

     19. The headings in this Warrant are for convenience only and shall not limit or otherwise affect the meaning hereof. 

     20. If any term, provision, covenant or restriction of this Warrant is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions,
covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their best efforts to find and employ an alternative means to achieve the
same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions,
covenants and restrictions without including any of such which may be hereafter declared invalid, illegal, void or unenforceable. 

     21. This Warrant is intended by the parties as a final expression of their agreement and intended to be a complete and exclusive statement of the agreement and understanding of the parties hereto in
respect of the subject matter contained herein and therein.  There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein and therein. This Warrant supersedes all prior agreements and
understandings between the parties with respect to such subject matter.

     22. In any action or proceeding brought to enforce any provision of this Warrant, or where any provision hereof is validly asserted as a defense, the prevailing party, as determined by the court,
shall be entitled to recover reasonable attorneys’ fees in addition to any other available remedy. 

     22. Each party hereto agrees to use all reasonable efforts to obtain all consents and approvals, and to do all other things, necessary for the transactions contemplated by this Warrant on or prior to
the end of the Exercise Period. The parties agree to take such further action and to deliver or cause to be delivered to each other after the date hereof such additional agreements or instruments as any of them may reasonably request for the purpose
of carrying out this Warrant and the agreements and transactions contemplated hereby and thereby. 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange
Act of 1934, as amended.

- 9 - 

     23. Notwithstanding anything herein to the contrary, the Warrants Shares shall not be transferable prior to July 1, 2009 and shall be transferable commencing on such date at the rate of 50,000 per
calendar month thereafter. Any number of Warrant Shares not sold during any calendar month commencing July 1, 2009 shall not be carried forward or cumulated to subsequent months. 

Dated:

	   	 	
GAMMACAN INTERNATIONAL, INC.   
	   
	   
	   	 	By: 	   
	   	 	   	
Name:   
	   	 	   	
Title:   
	   
	[Seal]
	   
	   
	   
	   	 	 	   	   
	
Secretary   	 	   	   

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange
Act of 1934, as amended.

- 10 - 

EXHIBIT I 

ELECTION TO PURCHASE 

     The undersigned hereby irrevocably elects to exercise Warrants represented by this Warrant and to purchase the shares of Common Stock or other securities issuable upon the exercise of said Warrants,
and requests that Certificates for such shares be issued and delivered as follows: 

	
ISSUE TO:   	   	   	 
	   	   	
(Name)   	 
	 	 	 	 
	 	 	 	 
	   	   	
(Address, Including Zip Code)   	 
	 	 	 	 
	 	 	 	 
	   	   	
(Social Security or Tax Identification Number)   	 
	 	 	 	 
	 	 	 	 
	
DELIVER TO:   	   	   	 
	   	   	
(Name)   	 
	 	 	 	 
	 	 	 	 
	   	   	
(Address, Including Zip Code)   	 

     In payment of the purchase price
with respect to this Warrant exercised, the undersigned hereby tenders payment
of $           by (i) certified
or bank cashiers check payable to the order of the Company o;
or (ii) a wire transfer of such funds to an account designated by the Company
o (check
applicable box). If the number of Warrant Shares
hereby exercised is fewer than all the Warrant Shares  represented by this Warrant,
the undersigned requests that a new Warrant representing the number of full Warrant
Shares not exercised to be issued and delivered as set forth below: 

	
Name of Holder or Assignee:   	   	 
	
   	(Please Print) 	 

	   
	   
	
Address:________________________________________   	   	   	   	   
	 	 	 	 	 
	             ________________________________________	   	   	   	   
	   
	   
	
Signature:______________________________   	   	
DATED:___________________________________________   	
 , 200__   
	
(Signature must conform in all respects to name of holder
as specified on the fact of this Warrant)   	   	   	   	   

	
Signature Guaranteed: ________________________________________  	 

EXHIBIT II 

ASSIGNMENT 

     FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto the Assignee named below all of the rights of the undersigned represented by the within Warrant, with respect to the number
of Warrant Shares set forth below: 

	 

  	 
  	 

  	 
  	 

  	 
  	
Taxpayer 
  
	 

  	 
  	 

  	 
  	
Number of 
  	 
  	
Identification 
  
	
Name of Assignee 
  	 
  	
Address 
  	 
  	
Warrant Shares 
  	 
  	
Number 
  

 

and does hereby irrevocably constitute and appoint ___________________, Attorney, to make such transfer on the Warrant Register maintained at the principal office of the Company with full power of substitution in the
premises. 

	
Dated:   	  
	 	  

	
             	 	 	Signature
	
(Signature must conform in all respects to name of holder as specified on the face of this Warrant).   
	   	 	 	 
	   	 	 	 
	   	 	 	 
	Signature Guaranteed:   	 	 
	 	 	 	 

Exhibit B 

[*] 

 

 

 

 

 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2
under the Securities Exchange Act of 1934, as amended.  

Exhibit C 

[*]

 

 

 

 

 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2
under the Securities Exchange Act of 1934, as amended.  

Exhibit D 

[*] 

 

 

 

 

 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2
under the Securities Exchange Act of 1934, as amended.Exhibit 10.1

EMPLOYMENT AGREEMENT

     This Employment Agreement (“Agreement”) dated as of June
26, 2004, is entered into by and between Deerfield Capital Management LLC (“Deerfield”), a Delaware limited liability company and
wholly owned subsidiary of Deerfield & Company LLC (“D&C”), an Illinois limited liability company, and Jonathan W. Trutter (“Employee”), and shall become effective as of (and subject to) the consummation of the transactions (collectively, the “Transaction”) contemplated by the Purchase Agreement, dated as of the date hereof, by and among Triarc Companies, Inc., Sachs Capital Management LLC, SLA Investments, Inc., Scott A. Roberts, Marvin Shrear, Gregory H. Sachs and any other
parties named therein (the “Purchase Agreement”) (the date of the consummation of the Transaction being referred to herein as the “Effective Date”). 

W I T N E S S E
T H

     WHEREAS, Deerfield desires to continue to employ Employee on and following the consummation of the Transaction and to have the benefit of Employee’s
services, and Employee similarly desires to continue to be employed by Deerfield, in each case pursuant to the terms and conditions hereof; and 

     WHEREAS, Deerfield and D&C wish to assure that their respective “Confidential Information” (as defined herein), which Employee obtains as a
result of Employee’s status as an employee of Deerfield, will remain confidential and that Deerfield’s and D&C’s business interests will be protected. 

     NOW, THEREFORE, in consideration of the mutual promises contained herein and for other valuable consideration, the sufficiency of which is hereby
acknowledged, IT IS AGREED AS FOLLOWS: 

     1. Employment. Deerfield hereby continues to employ Employee as Chief Investment
Officer of Deerfield, and Employee hereby agrees to continue such employment and agrees to perform the duties and responsibilities hereunder in accordance with the terms and conditions hereinafter set forth. 

        (a) Term. The term of Employee’s employment under this Agreement shall
    commence on the Effective Date and conclude on the day preceding the fifth anniversary of the Effective Date, unless sooner terminated according to Section 3 (the “Term”). Subject to Section 8(i), this Agreement shall terminate upon the expiration of the Term. 

        (b) Duties and Responsibilities. Employee shall devote Employee’s full time,
    business skills and attention to the performance of Employee’s duties, and shall have direct reporting responsibility to the President of Deerfield, and shall be available during normal business hours and at such times as may otherwise be
    required. Employee shall use Employee’s best efforts, expertise and knowledge to preserve, develop and maintain the interests of Deerfield and each “Affiliate” (as defined below) of Deerfield. Employee’s duties shall include
    working with other members of Deerfield, D&C or any of their respective 

2

  
    Affiliates in a professional, cooperative and efficient manner and such other duties as may from time to time be assigned by Deerfield; provided, that such duties are generally consistent with Employee’s skills and
      level of responsibility within the organization. Employee shall maintain all regulatory licenses and registrations necessary to the performance of Employee’s duties hereunder. Deerfield may require Employee to perform any of the duties set
    forth in this Section 1(b) on behalf of Deerfield, D&C or any of their respective direct or indirect subsidiaries. 

        (c) Outside Activities. During the Term, Employee shall not engage or otherwise be
    involved in any other business, trade or profession that creates an actual, potential or perceived conflict with the interests of Deerfield or any Affiliate of Deerfield, or that otherwise conflicts with Employee’s ability to perform
    Employee’s duties and responsibilities hereunder unless approved by the Board of Directors of D&C (the “Board”). 

     2. Compensation and Benefits. 

        (a) Base Salary. During the Term, Employee shall receive a
    base salary of no less than $416,250 per year (the “Base Salary”), payable in accordance with the payroll practices of Deerfield as in effect
      from time to time.

        (b) Bonus. 

      (i) Guaranteed
Bonus. During the Term, Employee shall participate
in the Bank Loan Group Bonus Program. For purposes of this Agreement, the “Bank
Loan Group Bonus Program” means the
bonus  program generally made available to members of Deerfield’s bank loan
group, as such program is in effect on the Effective Date. Deerfield hereby agrees
that the Bank Loan Group Bonus Program shall remain in effect during the Term.
 Notwithstanding the foregoing, with respect to each fiscal year completed during
the Term, commencing with the 2004 fiscal year, Employee’s total bonus(es),
including any bonus pursuant to the Bank Loan Group Bonus Program, for such year
shall  be no less than $783,750 (the “Guaranteed
Bonus”) 

     (ii) Retention Bonus. In the event that Employee remains employed by Deerfield or
an Affiliate of Deerfield through the day prior to the fifth anniversary of the Effective Date, Employee shall be entitled to receive a payment equal to $2,000,000 within 90 days following the fifth anniversary of the Effective Date (the
“Retention Bonus”). 

        (c) Business Expense Reimbursement. Employee shall be reimbursed for
    Employee’s reasonable and necessary business expenses, including reasonable travel, lodging and entertainment expenses, in accordance with Deerfield’s business expense reimbursement policy as in effect from time to time and upon submission
    of appropriate documentation and receipts within thirty (30) days of the date on which the expense is incurred. 

3

        (d) Profits Interest Grant. Within thirty (30) days following the Effective Date,
    Employee shall be awarded a profits-only membership interest in D&C representing 1.5% of the outstanding membership interests in D&C (the “Profits Interest Grant”), subject to the terms and conditions of a profits-only interest grant agreement to be entered into at the time of grant and any other agreement(s) required to be entered into pursuant thereto (the “Profits Interest Grant Agreement”). Subject to the terms of the Profits Interest Grant Agreement, the Profits Interest
      Grant shall vest as to one-third of the Profits Interest Grant on each of the third, fourth and fifth anniversaries of the Effective Date; provided, that Employee remains
        employed by Deerfield or an Affiliate of Deerfield on the day prior to each such anniversary, as applicable. 

        (e) Benefits. Employee will be entitled to participate in the medical, dental,
    life, long-term disability and retirement plans as may be in effect from time to time. 

        (f) Deductions. All salary and other payments and allowances outlined in this
    Agreement are subject to such withholding and deductions as may be required by law, as determined by Deerfield in its sole discretion. 

        (g) KEEP Plan. In connection with entering into this Agreement, Employee hereby
    waives any rights Employee has as a participant in D&C’s Key Employee Equity Participation Plan (the “KEEP Plan”) and with respect to any outstanding share
      appreciation rights granted to Employee pursuant to the KEEP Plan, and agrees that such share appreciation rights shall be cancelled without further consideration effective as of the Effective Date. 

     3. Termination.

        (a) Termination by Deerfield without Cause; Termination by Employee for Good Reason.

     (i) This Agreement and Employee’s employment may be terminated at any time prior to the day preceding the fifth
anniversary of the Effective Date by Deerfield without “Cause” (as defined below) (other than by reason of Employee’s death or “Disability” (as defined below)) following the delivery of a “Notice of Termination”
(as defined below) to Employee. In addition, this Agreement and Employee’s employment hereunder may be terminated at any time prior to the day preceding the fifth anniversary of the Effective Date by Employee for “Good Reason” (as
defined below) following the delivery of a Notice of Termination to Deerfield. 

     (ii) If Employee’s employment is terminated by Deerfield without Cause (other than by reason of Employee’s death
or Disability) or by Employee for Good Reason (A) Employee shall be entitled to receive any earned but unpaid bonus for any fiscal year preceding the fiscal year in which the termination occurs, (B) Employee shall continue to receive the Base Salary
and 

4

Guaranteed Bonus payment(s) Employee would have received for the three years following the effective date of termination in accordance with the normal payroll and bonus payment practices of Deerfield and (C) Deerfield will
pay Employee the Retention Bonus within 90 days following the fifth anniversary of the Effective Date. Except as set forth above, Employee shall have no further rights to any compensation (including any Base Salary or Guaranteed Bonus) or any other
benefits under this Agreement. All other benefits, if any, due Employee following a termination pursuant to this Section 3(a) shall be determined in accordance with the plans, policies and practices of Deerfield; provided, however, that Employee shall not participate in any severance plan, policy or program of Deerfield. 

     (iii) For purposes of this Agreement, “Good Reason” shall mean, without Employee’s consent, the occurrence of any of the following events: (A) a reduction by Deerfield in Employee’s Base Salary; (B) any adverse change in Employee’s title or responsibilities; (C) any
requirement of Deerfield that Employee be based anywhere more than fifty (50) miles outside the city limits of Chicago, IL; or (D) a failure by Deerfield to pay Employee’s Base Salary or Guaranteed Bonus when due pursuant to this Agreement.
Notwithstanding the foregoing, “Good Reason” shall not exist with respect to the matters set forth in clauses (A), (B), (C) or (D) above if, after written notice from Employee to the Board specifying the circumstances giving rise to Good
Reason under such clause, Deerfield shall have cured the circumstances giving rise to Good Reason to the reasonable satisfaction of Employee within ten (10) business days after such notice. 

        (b) Termination for Cause. 

     (i) This Agreement and Employee’s employment may be terminated by Deerfield at any time for Cause following delivery of a Notice of Termination to Employee. 

     (ii) For purposes of this Agreement “Cause” shall mean: (A) the breach by Employee of any material provision of this Agreement, including, but not limited to, Sections 5, 6 and 7, or the Profits Interest Grant Agreement; (B) Employee’s commission of a felony or
violation of any law involving moral turpitude, dishonesty, disloyalty or fraud; (C) any failure by Employee to substantially comply with any written rule, regulation, policy or procedure of Deerfield or any Affiliate of Deerfield applicable to
Employee, which noncompliance could reasonably be expected to have a material adverse effect on the business of Deerfield or any such Affiliate; (D) any failure by Employee to comply with Deerfield’s, or any Affiliate of Deerfield’s,
policies with respect to insider trading applicable to Employee; (E) a willful material misrepresentation at any time by Employee to any member of the Board or any director or superior executive officer of Deerfield or any of its Affiliates; (F)
Employee’s willful failure or refusal to comply with any of Employee’s material obligations hereunder or a reasonable and lawful instruction of the Board or the person to 

5

whom Employee reports; or (G) commission by Employee of any act of fraud or gross negligence in the course of Employee’s employment hereunder or any other action by Employee, in either case that is determined to be
detrimental to Deerfield or any of its Affiliates (which determination, in the case of gross negligence or such other action, shall be made by the Board in its reasonable discretion); provided, however, that, except for any willful or grossly negligent acts or omissions, the commission of any act or omission described in clause (A) or (C) that is
capable of being cured shall not constitute Cause hereunder unless and until Employee, after written notice from Deerfield to Employee specifying the circumstances giving rise to Cause under such clause, shall have failed to cure such act or
omission to the reasonable satisfaction of the Board within ten (10) business days after such notice. 

     (iii) In the event Employee’s employment is terminated pursuant to this Section 3(b), Employee shall be entitled to
receive Employee’s Base Salary through the date of termination and any earned but unpaid Guaranteed Bonus for any fiscal year preceding the fiscal year in which the termination occurs. Employee shall have no further rights to any compensation
(including any Base Salary or Guaranteed Bonus) or any other benefits under this Agreement. All other benefits, if any, due Employee following a termination pursuant to this Section 3(b) shall be determined in accordance with the plans, policies and
practices of Deerfield; provided, however, that Employee shall not participate in any severance plan,
policy or program of Deerfield. 

        (c) Termination due to Death or Disability. This Agreement and Employee’s
    employment shall terminate immediately upon Employee’s death or, following delivery of a Notice of Termination by Deerfield to Employee, due to Employee’s Disability. In the event Employee’s employment is terminated pursuant to this
    Section 3(c), Employee (or Employee’s estate, as the case may be) shall be entitled to receive Employee’s Base Salary through the date of termination and any earned but unpaid Guaranteed Bonus for any fiscal year preceding the fiscal year
    in which the termination occurs. Employee (or Employee’s estate, as the case may be) shall have no further rights to any compensation (including any Base Salary or Guaranteed Bonus) or any other benefits under this Agreement. All other
    benefits, if any, due Employee (or Employee’s estate, as the case may be) following a termination pursuant to this Section 3(c) shall be determined in accordance with the plans, policies and practices of Deerfield; provided, however, that Employee (or Employee’s estate, as the case may be) shall not participate in any severance plan,
      policy or program of Deerfield. For purposes of this Agreement, “Disability” shall mean: Employee’s physical or mental incapacity as a result of which Employee
        is unable for a period of ninety (90) days during any one hundred eighty (180) day period to perform Employee’s duties with substantially the same level of quality as immediately prior to such incapacity. 

        (d) Notice of Termination. Any termination of this Agreement and Employee’s
    employment by Deerfield (other than the immediate and automatic 

6

  
    termination of this Agreement and Employee’s employment upon Employee’s death) shall be communicated by a written Notice of Termination to Employee or, in the case of a termination by Employee for Good Reason, to
    Deerfield, delivered in accordance with Section 8(m). For purposes of this Agreement, a “Notice of Termination” shall mean a notice that indicates the specific
        termination provision in this Agreement relied upon and the date of termination, as determined by Deerfield or, in the case of a termination by Employee for Good Reason, the circumstances alleged to give rise to Good Reason, and which date of
        termination shall be at least five (5) business days following the date on which Employee gives the Notice of Termination to Deerfield. 

        (e) Obligations Following Notice. If this Agreement and Employee’s employment
    are terminated, Employee shall, prior to the effective date of such termination or as may otherwise be agreed by Deerfield and Employee, (i) meet with Employee’s supervisors as requested by Deerfield for the purpose of winding up any pending
    work and providing an orderly transfer of the duties, accounts, customers and/or clients for which Employee has been responsible, identifying key Confidential Information likely to be in Employee’s possession, and discussing Employee’s
    future plans for employment in light of Employee’s obligations under this Agreement and the Profits Interest Grant Agreement; (ii) promptly deliver to Deerfield all property belonging to Deerfield and any of its Affiliates, including any and
    all Confidential Information, equipment (including, without limitation, any cell phones, computers, printers, fax machines, pagers, Personal Digital Assistants, Bloomberg terminals or Travellers, and Reuters terminals), automobiles and other
    property of Deerfield or any of its Affiliates that may be in Employee’s possession or under Employee’s control, whether at Deerfield’s offices, Employee’s home or elsewhere, including all such papers, work papers, notes,
    documents and equipment in the possession of Employee or Employee’s counsel and any copies or duplicates thereof, and all originals and copies of papers, notes and documents (in any medium, including computer disks), whether property of
    Deerfield or any of its Affiliates or not, prepared, received or obtained by Employee or Employee’s counsel during the course of Employee’s employment with Deerfield or any of its Affiliates; and (iii) devote Employee’s full time and
    attention to these obligations and Employee’s other responsibilities as directed by Deerfield. Moreover, if Employee’s employment is terminated pursuant to Section 3(a) by Deerfield without Cause (other than by reason of Employee’s
    death or Disability), by Employee for Good Reason, or by Deerfield pursuant to Section 3(c) due to Employee’s Disability, the continued payment of Base Salary, and the right to receive payment in respect of vested profits-only membership
    interests granted pursuant to the Profits Interest Grant Agreement, as applicable, shall be subject to Employee’s execution of a release, in substantially the form attached hereto as Exhibit A, subject to revision to reflect changes in
    applicable law. 

     4. Definitions. For purposes of Sections 5, 6 and 7 of this Agreement (and
otherwise where used in this Agreement), the following terms shall have the meanings set forth herein: 

7

        (a) “Affiliate” shall mean, with
    respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with that first Person. For purposes of this definition, “control” of a Person shall mean the power, direct or
    indirect, to direct or cause the direction of the management and policies of such Person, whether through the ownership of Voting Stock, by contract, or otherwise. When referencing an “Affiliate” of Deerfield or D&C in this Agreement,
    the parties specifically acknowledge that such term includes Triarc and its Affiliates and shall include any Affiliate that may be organized in the future. 

        (b) “Client” shall mean all Past
    Clients, Present Clients and Potential Clients, subject to the following general rules: (i) with respect to each such Client, the term shall also include any Persons that, to the Knowledge of Employee, are Affiliates of such Client, directors,
    officers or employees of such Client or any such Affiliates thereof, or Persons who are members of the Immediate Family of any of the foregoing Persons or Affiliates of any of them; (ii) with respect to any such Client that is a collective
    investment vehicle (provided that, for the avoidance of doubt, a 401(k) retirement plan shall not itself be considered a “collective investment vehicle” except to the extent Employee has actual knowledge of the identities of investors
    therein), the term shall also include any investor or participant in such Client (provided that, in the case of any collective investment vehicle that is a registered investment company, an investor or participant therein shall not be deemed a
  “Client” hereunder unless such investor or participant has in the aggregate at least $500,000 under management by Deerfield and its Affiliates (whether through investments in registered investment companies or otherwise)); and (iii)
    with respect to any such Client that is a trust or similar entity, the term shall include the settler and each of the beneficiaries of such Client and the Affiliates and Immediate Family members of any such Persons. 

        (c) “Confidential Information” shall
    mean all proprietary information or data relating to the business of Deerfield or any of its Affiliates to which Employee has access and/or learns prior to or during the Term, including, but not limited to: business and financial information; new
    product development; formulas, identities of and information concerning Clients, vendors and suppliers; development, expansion and business strategies, plans and techniques; computer programs, devices, methods, techniques, processes and inventions;
    research and development activities; compilations and other materials developed by or on behalf of Deerfield, D&C or any of their respective Affiliates (whether in written, graphic, audio-visual, electronic or other media, including computer
    software). Confidential Information also includes information of any third party doing business with Deerfield or any of its Affiliates that such third party identifies as being confidential or that is subject to a confidentiality agreement with
    such third party. Confidential Information shall not include any information that is in the public domain or otherwise publicly available (other than as a result of a wrongful act of Employee or an agent or other employee of Deerfield or any of its
    Affiliates, including a breach of Section 5(b) below). 

8

        (d) “Immediate Family” shall mean, with
    respect to any individual, such individual’s spouse; the descendants (natural or adoptive, of the whole or half blood) of such individual or such individual’s spouse; the parents and grandparents (natural or adoptive) of such individual or
    such individual’s spouse; and the descendants of the parents (natural or adoptive) of such individual or such individual’s spouse. 

        (e) “Investment Management Services”
    shall mean any services (including sub-advisory services) that involve (a) the management of an investment account or fund (or portions thereof), or a group of investment accounts or funds, of any Person for compensation or (b) the rendering of
    advice with respect to the investment and reinvestment of assets or funds (or any group of assets or funds) of any Person for compensation (but excluding the rendering of such advice to any subsequent employer of Employee that is not in the business
    of managing investment accounts or funds or rendering advice to or for the benefit of third parties with respect to investment or reinvestment of assets or funds, where such advice is rendered solely for such employer’s own proprietary use and
    the only compensation received by Employee is in the form of salary, wages or bonus paid by such employer), and, in the case of both (a) and (b), performing activities related or incidental thereto. 

        (f) “Knowledge of Employee” shall mean
    Employee’s actual knowledge or the knowledge Employee should have obtained after making due inquiry.

        (g) “Past Client” shall mean any Person
    who, to the Knowledge of Employee, had been an advisee or investment advisory customer of, or was otherwise a recipient of Investment Management Services from, Deerfield or any of its Affiliates at any time during the one (l) year period immediately
    preceding the date of termination of Employee’s employment, but at such date is not an advisee or investment advisory customer or client of, or recipient of Investment Management Services from, Deerfield or any of its Affiliates. 

        (h) “Person” or “Persons” means any individual, corporation, partnership, joint venture, association, joint-stock company, business trust, limited liability company, trust, unincorporated organization or
    government or a political subdivision, agency or instrumentality thereof or other entity or organization of any kind.

        (i) “Potential Client” shall mean any
    Person to whom Employee or, to the Knowledge of Employee, Deerfield or any of its Affiliates, or any owner, part owner, shareholder, partner, member, director, officer, trustee, employee, agent or consultant (or Person acting in a similar capacity)
    of any such Person (acting on their behalf), has, within the one (l) year period prior to the date of termination of Employee’s employment, offered (whether by means of a personal meeting or by telephone call, letter, written proposal or
    otherwise) to provide Investment Management Services, but who is not on the date of termination of Employee’s

9

  
    employment an advisee or investment advisory customer of, or otherwise a recipient of Investment Management Services from, Deerfield or any of its Affiliates (directly or indirectly). The preceding sentence is meant to
      exclude (i) advertising, if any, through mass media in which the offer, if any, is available to the general public, such as magazines, newspapers and sponsorships of public events and (ii) “cold calls” and mass-mailing form letters, in
    each case to the extent not directed towards any particular Person and not resulting in an indication of interest or a request for further information. 

        (j) “Present Client” shall mean, at any
    particular time, any Person who, to the Knowledge of Employee, at the time of Employee’s employment or thereafter is an advisee or investment advisory customer of, or otherwise a recipient of Investment Management Services from, Deerfield or
    any of its Affiliates (directly or indirectly).

        (k) “Prohibited Competition Activity”
    shall mean any of the following activities:

        (i) directly or indirectly, whether as owner, part owner, partner, shareholder, member, director, officer, trustee,
    employee, agent or consultant (or Person acting in a similar capacity) for or on behalf of any Person other than Deerfield or any of its Affiliates: (A) diverting or taking away any funds or investment accounts with respect to which Deerfield or any
    of its Affiliates is performing Investment Management Services (other than funds of which Employee and/or members of Employee’s Immediate Family are the sole beneficial owners, subject to any applicable restrictions relating thereto set forth
    in any agreement to which Employee or any of Employee’s Affiliates is a party); or (B) soliciting any Person to divert or take away any such funds or investment accounts (other than funds of which Employee and/or members of Employee’s
    Immediate Family are the sole beneficial owners, subject to any applicable restrictions relating thereto set forth in any agreement to which Employee or any of Employee’s Affiliates is a party); or 

        (ii) directly or indirectly, whether as owner, part owner, partner, shareholder, member, director, officer, trustee,
    employee, agent or consultant (or Person acting in a similar capacity) for or on behalf of any Person other than Deerfield or any of its Affiliates, performing any Investment Management Services (provided that if Employee directly performs
    Investment Management Services for Employee’s own account or a member of Employee’s Immediate Family without a fee or other remuneration, Employee shall not be considered to have engaged in a Prohibited Competition Activity solely due to
    the performance of such Investment Management Services).

        (l) “Triarc” shall mean Triarc
    Companies, Inc. and any entity to which it has assigned its rights, interest and obligations under the Purchase Agreement, together with its successors and assigns.

10

        (m) “Voting Stock” means, with respect
    to any Person, the capital stock or other equity or profits interests of any class or kind ordinarily having the power to vote for the election of directors, managers or other voting members of the governing body of such Person. 

     5. All Business to be the Property of Deerfield; Assignment of Intellectual Property; Confidentiality. 

        (a) Employee agrees that any and all presently existing investment advisory businesses of D&C, Deerfield and their
    respective Affiliates (including businesses of any of their predecessors), and all businesses developed by D&C, Deerfield, any of their respective Affiliates or any predecessor thereto, including by Employee or any other employee of D&C,
    Deerfield, any of their respective Affiliates or any predecessor thereto, including, without limitation, all investment methodologies, all investment advisory contracts, fees and fee schedules, commissions, records, data, client lists, agreements,
    trade secrets, and any other incident of any business developed by D&C, Deerfield, any of their respective Affiliates or any predecessor thereto, or earned or carried on by Employee for D&C, Deerfield, any of their respective Affiliates or
    any predecessor thereto, and all trade names, service marks and logos under which D&C, Deerfield, any of their respective Affiliates or any predecessor thereto, do or have done business, and any combinations or variations thereof and all related
    logos, are and shall be the exclusive property of D&C, Deerfield or such Affiliate, as applicable, for its or their sole use, and (where applicable) shall be payable directly to D&C, Deerfield or such Affiliate (as applicable). In addition,
    Employee acknowledges and agrees that the investment performance of the accounts or funds managed by D&C, Deerfield or any of their respective Affiliates, or any predecessor thereto, was attributable to the efforts of the team of professionals
    at D&C, Deerfield, such Affiliate or such predecessor thereto, and not to the efforts of any single individual or subset of such team of professionals, and that therefore, the performance records of the accounts or funds managed by D&C,
    Deerfield or any of their respective Affiliates, or any predecessor thereto, are and shall be the exclusive property of D&C, Deerfield or such Affiliate, as applicable (and not of any other Person or Persons), and may not be used by Employee
    except with the prior written consent of the Board. 

        (b) Employee acknowledges that, in the course of performing services hereunder and otherwise (including, without
    limitation, for Deerfield’s predecessors), Employee has had, and will from time to time have, access to Confidential Information, including without limitation, confidential or proprietary investment methodologies, trade secrets, proprietary or
    confidential plans, client identities and information, client lists, service providers, business operations or techniques, records and data (“Intellectual Property”)
      owned or used in the course of business by D&C, Deerfield or any of their respective Affiliates. Employee agrees always to keep secret and not ever publish, divulge, furnish, use or make accessible to anyone (otherwise than in the regular
      business of D&C, Deerfield and their respective Affiliates or as required by court order or by law (after 

11

  
    consultation with outside counsel)) any Confidential Information of D&C, Deerfield or any of their respective Affiliates. At the termination of Employee’s services to Deerfield or any of its Affiliates for any
      reason, all data, memoranda, client lists, notes, programs and other papers, items and tangible media, and reproductions thereof relating to the foregoing matters in Employee’s possession or control, shall be returned to Deerfield or the
    applicable Affiliate and remain in its possession. 

        (c) In accordance with Section 3 of the Illinois Employee Patent Act, Illinois Public Act 83-493, Employee is hereby
    advised that, notwithstanding any other provision of this Section 5 to the contrary, Employee shall not be required to assign to D&C, Deerfield or any of their respective subsidiaries, any invention, discovery or improvement conceived or made by
    Employee for which no equipment, supplies, facility or Confidential Information of D&C, Deerfield or any of their respective subsidiaries was used and that was developed exclusively and entirely on Employee’s own time unless such invention,
    discovery or improvement (i) relates to the business or the demonstrably anticipated research or development of D&C, Deerfield or any of their respective subsidiaries or (ii) results from or relates to any work performed by Employee for D&C,
    Deerfield or any of their respective subsidiaries. 

     6. Non-Competition and Other Covenants. 

        (a) During the Term and (i) in the event of the termination of Employee’s employment with Deerfield and its Affiliates by Deerfield without Cause or by Employee for Good Reason prior to the day preceding the fifth anniversary of the Effective Date, for the period commencing on the
    date of Employee’s termination hereunder and ending on the third anniversary of such date of termination, (ii) in the event of the termination of Employee’s employment with Deerfield and its Affiliates for any reason other than by
    Deerfield without Cause or by Employee for Good Reason prior to the day preceding the fifth anniversary of the Effective Date, for the period commencing on the date of Employee’s termination hereunder and ending on the later of (x) the fifth
    anniversary of the Effective Date or (y) the second anniversary of such date of termination or (iii) in the event of Employee’s termination of Employee’s employment with Deerfield and its Affiliates for any reason on or after the day
    preceding the fifth anniversary of the Effective Date, for the period commencing on the date of Employee’s termination and ending on the second anniversary of such date of termination (in the case of each of (i), (ii) or (iii) the
  “Non-Competition Period”), Employee shall not, directly or indirectly, engage in any Prohibited Competition Activity without the prior written consent of the Board,
    which consent may (or may not) be provided at the sole discretion of the Board. 

        (b) In addition to, and not in limitation of, the provisions of Section 6(a), Employee agrees, for the benefit of Deerfield and its Affiliates, that during the Term and (i) in the event of the termination of Employee’s employment with Deerfield and its Affiliates by Deerfield
    without Cause or by 

12

  
    Employee for Good Reason, for the period commencing on the date of Employee’s termination hereunder and ending on the third anniversary of such date of termination, or (ii) in the event of the termination of
      Employee’s employment with Deerfield and its Affiliates for any reason other than by Deerfield without Cause or by Employee for Good Reason, for the period commencing on the date of Employee’s termination hereunder and ending on the
      seventh anniversary of the Effective Date, Employee shall not, directly or indirectly, whether as owner, part owner, shareholder, partner, member, director, officer, trustee, employee, agent or consultant, or in any other capacity, on behalf of
    Employee or any Person other than Deerfield or its Affiliates, without the prior written consent of the Board, which consent may (or may not) be provided at the sole discretion of the Board: 

     (i) provide Investment Management Services to any Person that is a Past Client, Present Client or Potential Client;
provided, however, that this clause (i) shall not be applicable to Clients (including Potential
Clients) who are also members of the Immediate Family of Employee; 

     (ii) solicit or induce, whether directly or indirectly, any Person for the purpose (which need not be the sole or primary
purpose) of (A) causing any funds (other than funds of which Employee and/or members of Employee’s Immediate Family are the sole beneficial owners) with respect to which Deerfield or any of its Affiliates provides Investment Management Services
to be withdrawn from such management, or (B) causing any Client (including any Potential Client) not to engage Deerfield or any of its Affiliates to provide Investment Management Services for any additional funds; provided, however, that this clause (ii)(B) shall not be applicable to Clients (including Potential Clients) who are also
members of the Immediate Family of Employee; 

     (iii) contact or communicate with, whether directly or indirectly, any Past, Present or Potential Clients in connection
with Investment Management Services; provided, however, that this clause (iii) shall not be applicable
to Clients (including Potential Clients) who are also members of the Immediate Family of Employee; or 

     (iv) (A) solicit or induce, or attempt to solicit or induce, directly or indirectly, any employee or agent of, or
consultant to, Deerfield or any of its Affiliates to terminate its, his or her relationship therewith, (B) hire or engage any employee, external researcher or similar agent or consultant, or former employee, external researcher or similar agent or
consultant of Deerfield or any of its Affiliates who was employed by or acted as an external researcher or similar agent or consultant of Deerfield or any of its Affiliates at any time during the eighteen (18) month period preceding such hiring or
engagement of such Person; or 

     (v) work in any enterprise, or any division of an enterprise, the business of which enterprise or division, as the case
may be, primarily involves 

13

the provision of Investment Management Services, with any employee, external researcher or similar agent or former employee, external researcher or similar agent of Deerfield or any of its Affiliates who, to the Knowledge
of Employee, was employed by or acted as an agent to Deerfield or any of its Affiliates at any time during the twelve (12) month period preceding the termination of Employee’s employment (excluding for all purposes of this sentence, secretaries
and persons holding other similar positions). 

Notwithstanding the provisions of Sections 6(a) and 6(b), Employee may make passive personal investments in an enterprise that is competitive with Deerfield or any of its Affiliates, the shares or other equity interests of
which are publicly traded; provided that, Employee’s holdings therein, together with any holdings of Employee’s Affiliates and members of Employee’s Immediate
Family, are less than five percent (5%) of the outstanding shares or comparable interests in such entity. 

        (c) Employee and Deerfield agree that the periods of time and the unlimited geographic area applicable to the covenants of
    this Section 6 are reasonable in view of (i) Employee’s receipt of the Profits Interest Grant (and Employee’s resulting status as a member of D&C from and after the date all or a portion of such Profits Interest Grant vests), (ii)
    Employee’s receipt of the payments specified in Sections 2 and (if applicable) 3 above, (iii) the geographic scope and nature of the business in which Deerfield and its Affiliates are engaged (including Deerfield’s predecessors), including
    the geographic location of its Clients, (iv) Employee’s knowledge of Deerfield’s and its Affiliates’ businesses, (v) Employee’s relationships with Deerfield’s and its Affiliates’ investment advisory clients and (vi)
    Employee’s continued employment with Deerfield and Employee’s receipt of other payments and benefits pursuant to this Agreement. However, if such period or such area nonetheless should be adjudged unreasonable in any judicial proceeding,
    then the period of time shall be reduced by such number of months or such area shall be reduced by elimination of such portion of such area, or both, as are deemed unreasonable, so that this covenant may be enforced in such maximum area and during
    such maximum period of time as are adjudged to be reasonable. 

        (d) Employee agrees (on behalf of Employee and Employee’s Affiliates) not to make any communication to any third
    party (including, by way of example and not of limitation, any Client (including Potential Clients) or employee of Deerfield or any of its Affiliates) that would, or is reasonably likely to, disparage, create a negative impression of, or in any way
    be harmful to the business or business reputation of Deerfield or any of its Affiliates or their respective successors and assigns, and the then current and former officers, directors, shareholders, partners, members, employees, agents and
    consultants (or Person acting in a similar capacity) of each of the foregoing. 

        (e) Notwithstanding anything in Section 6(a) and 6(b) to the contrary, in the event of the termination of Employee’s
    employment with Deerfield and its 

14

  
    Affiliates by Deerfield without Cause or by Employee for Good Reason prior to the day preceding the fifth anniversary of the Effective Date, following the Non-Competition Period set forth in Section 6(a)(i), Employee may
    disclose Employee’s own record of achievement with Deerfield, including summary information about the performance of the bank loan group for which Employee has been the principal portfolio manager. 

     7. Remedies upon Breach; No Effect on Similar Covenants Elsewhere.

        (a) In the event that Employee breaches any of the covenants or agreements set forth in Sections 5 or 6 of this Agreement or materially breaches any other covenant or agreement set forth in any other Section of this Agreement, whether during the Term or following the termination of
    Employee’s employment with Deerfield for any reason, then in any such case (i) Employee shall forfeit Employee’s and Employee’s Affiliates’ rights to any equity, and D&C (and any of its assignees thereunder) shall have no
    further obligations, under any agreement related to the grant, award, issuance or sale of equity interests in D&C entered into between D&C and Employee (or any Affiliate thereof), including this Agreement and the Profits Interest Grant
    Agreement, and (ii) Deerfield, D&C and any of their respective Affiliates shall be entitled to withhold any other payments to which Employee (or any Affiliate thereof) would otherwise be entitled hereunder, under the Profits Interest Grant
    Agreement or otherwise, to offset damages resulting from such breach. 

        (b) Employee agrees that any breach of any of the covenants contained in this Agreement by Employee could cause
    irreparable damage to Deerfield and its Affiliates, and that Deerfield and/or any of its Affiliates (or the successors or assigns of any of them) shall have the right to specific performance and/or an injunction or other equitable relief (in
    addition to other legal remedies) to enforce or prevent any violation of Employee’s obligations hereunder. Nothing in this Agreement shall be construed as limiting Deerfield’s, any of its Affiliates’ or their successors’ or
    assigns’ protections and remedies under any applicable statute or common law cause of action. 

        (c) The covenants of Employee contained in Sections 5 and 6 of this Agreement are in addition to, and not in lieu of, any
    similar covenants contained in the Profits Interest Grant Agreement or in any other document. 

     8. Miscellaneous. 

        (a) Severability. Whenever possible,
    each section, portion and provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law. If any section, portion or provision of this Agreement, however, is held to be invalid, illegal or
    unenforceable in any respect under any applicable law or rule in any jurisdiction, and a court of competent jurisdiction or an arbitrator cannot modify such section, portion or provision or enforce the modified section, portion or provision, such
    invalidity, illegality or 

15

  
    unenforceability will not affect any other section, portion or provision, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable section, portion or
    provision had never been contained herein. 

        (b) Governing Law; Jurisdiction and Venue; Jury Trial Waiver. Notwithstanding
    principles of conflicts of law of any jurisdiction to the contrary, all terms and provisions of this Agreement are to be construed and governed by the internal laws of the State of Illinois. Any and all proceedings relating to Section 4, Section 5,
    Section 6, and, solely as it relates to Section 4, Section 5 or Section 6, Section 7 hereof shall, at the sole option of Deerfield, be maintained in either the courts of the State of Illinois or the federal District Courts sitting in Cook County,
    Illinois or the courts of the state of New York or the federal District Courts sitting in Manhattan, New York and Employee hereby agrees to submit to the personal jurisdiction of such court and not to argue that such court is forum non conveniens. THE PARTIES EXPRESSLY AND KNOWINGLY WAIVE ANY RIGHT TO A JURY TRIAL IN THE EVENT ANY ACTION ARISING UNDER OR IN CONNECTION WITH THIS
      AGREEMENT IS LITIGATED OR HEARD IN ANY COURT. 

        (c) Post-Termination Covenant. Following the termination of Employee’s
    employment for any reason, Employee agrees to cooperate, at the expense of Deerfield, with D&C, Deerfield and any of their respective Affiliates with respect to any litigation, administrative proceedings or investigation relating to the
    activities of D&C, Deerfield or any of their respective Affiliates during the period of Employee’s employment with Deerfield including, without limitation, being available for depositions and to be a witness at any trial or proceedings,
    help in preparation of any legal documentation and providing affidavits and any advice or support that D&C, Deerfield or any Affiliate thereof may request of Employee in connection with such litigation, proceeding or investigation. 

        (d) Dispute Resolution. Except to the extent contemplated by Section 8(b) of this
    Agreement, all disputes arising in connection with Employee’s employment hereunder or any rights arising pursuant to this Agreement shall be resolved by binding arbitration in accordance with the applicable rules of the American Arbitration
    Association. The arbitration shall be held in Cook County, Illinois before a single arbitrator selected in accordance with Section 11 of the American Arbitration Association Commercial Arbitration Rules who shall have (i) substantial business
    experience in the investment advisory industry, and shall otherwise be conducted in accordance with the American Arbitration Association Commercial Arbitration Rules and (ii) the right to award to any party any right or remedy that is available
    under applicable law. The award of the arbitrator shall be final and binding and may be entered and enforced in any court of competent jurisdiction. The language of arbitration shall be English. 

16

        (e) Employee’s Representations and Warranties. 

     (i) Employee represents
and warrants that, except as may be provided by law, Employee is not covered by any employment agreement, covenant not to compete, confidentiality agreement or any other contractual or other obligation that would preclude Employee from entering into this
Agreement or from using Employee’s best efforts to perform Employee’s duties and responsibilities under this Agreement. 

     (ii) Employee represents and warrants that Employee has had an opportunity to be represented by legal counsel in
connection with this Agreement. 

        (f) Effect of Waiver or Consent. A waiver or consent, express or implied, of or to
    any breach or default by Employee in the performance by Employee of Employee’s obligations to Deerfield or any of its Affiliates under this Agreement is not a waiver or consent of or to any other breach or default in the performance by Employee
    of the same or any other obligations of Employee with respect to Deerfield or any of its Affiliates. No failure or delay on the part of any party hereto in the exercise of any right hereunder shall impair such right or be construed to be a waiver
    of, or acquiescence in, any breach of any representation, warranty or agreement herein, nor shall any single or partial exercise of any such right preclude any other or further exercise thereof or of any other right. 

        (g) Entire Agreement. This Agreement constitutes the entire agreement between the
    parties as of the Effective Date and supersedes all previous agreements and understandings between the parties with respect to the subject matter hereof, including Employee’s employment agreement with Deerfield and D&C dated January 1, 2002
    (the “Prior Employment Agreement”). Employee hereby acknowledges and agrees that the Prior Employment Agreement shall terminate as of immediately prior to the
      Effective Date, Employee shall have no further rights thereunder and Deerfield and its Affiliates shall have no further obligations thereunder. 

        (h) Further Assurances. The parties hereto agree to execute and deliver to each
    other such other documents and to do such other acts and things that the other party may reasonably request for the purpose of carrying out the intent of this Agreement and the documents referred to in this Agreement. 

        (i) Survival. Sections 3, 4, 5, 6, 7 and 8 shall survive and continue in full
    force and effect in accordance with their terms notwithstanding the termination of this Agreement and Employee’s employment for any reason. 

        (j) Third Party Beneficiaries; Assignability. Triarc, its Affiliates and each of
    the other Affiliates of Deerfield are intended third-party beneficiaries of the provisions of this Agreement. This Agreement may be assigned by Deerfield 

17

  
    without the consent of Employee. This Agreement and all of the provisions hereof shall inure to the benefit of and be binding upon Deerfield and its successors and assigns and, to the extent relevant, to Deerfield’s
      Affiliates and their respective successors and assigns. This Agreement shall inure to the benefit of and be binding upon Employee’s heirs, executives, administrators and legal personal representatives, but Employee may not assign
    Employee’s rights or obligations hereunder without the prior written consent of Deerfield. 

        (k) Effectiveness of This Agreement. Notwithstanding anything to contrary herein,
    this Agreement shall not become effective until the Effective Date, i.e., if and only if the Transaction is consummated. If the Purchase Agreement is terminated in accordance
      with its terms, or if the Transaction is not otherwise consummated, then this Agreement shall be of no force or effect, and the Prior Employment Agreement shall remain in effect in accordance with its terms. 

        (l) Captions. The captions used in this Agreement are for convenience of reference
    only and do not constitute a part of this Agreement and will not be deemed to limit, characterize or in any way affect any provision of this Agreement, and all provisions of this Agreement will be enforced and construed as if no captions had been
    used in this Agreement. 

        (m) Notices. All notices, requests, demands and other communications required or
    permitted to be given hereunder shall be deemed given upon receipt, and may be given by personal delivery, certified mail (return receipt requested), facsimile or nationally recognized overnight courier service. 

  
  If to Employee: 

  

  Jonathan W. Trutter 

  830 Lake Road            

  Lake Forest, Ill 60045 

  

  If to Deerfield: 

  

  Deerfield Capital Management LLC 

  8700 West Bryn Mawr Ave., 12 Floor

  Chicago, Illinois 60631 

  Attention: General Counsel 

  Fax No.: (773) 380-1695 

  
  with a copy to: 

  

  Triarc Companies, Inc. 

  280 Park Avenue 

  New York, New York 10017

  Attention: General Counsel 

  Fax No.: (212) 451-3216 

18

        (n) Legal Indemnification. Deerfield shall indemnify and hold harmless Employee
    from and against, and Deerfield shall reimburse Employee’s expenses incurred in connection with, any losses, damages, fines, penalties, liabilities, costs and expenses (including attorneys’ fees and court costs) to which Employee may
    become subject that arise out of the actions or omissions of Employee in connection with Employee’s activities or alleged activities taken in good faith by Employee in Employee’s capacity as an employee of Deerfield (“Losses”); provided that (i) Employee is in full compliance with all terms, conditions, representations and
      warranties set forth in this Agreement; (ii) Employee promptly notifies Deerfield of any claim made or litigation filed against Employee; (iii) Employee does not settle or compromise the claim or litigation as to Employee without Deerfield’s
      prior written consent; and (iv) Deerfield’s own legal counsel shall defend Employee in connection with any such Losses unless otherwise agreed between the parties. Notwithstanding the foregoing, the duty of Deerfield to indemnify and hold
      harmless Employee and the obligation to reimburse Employee under this Section 8(n) will not extend beyond the maximum protection permitted by the law of the state of incorporation of Deerfield and shall in no event extend to actions or omissions
      constituting gross negligence, willful misconduct, fraud, misrepresentation, bad faith, criminal conduct or a basis for termination for Cause of Employee’s employment hereunder. To the extent that Deerfield advances Employee any amounts with
      respect to such Losses, Employee shall repay Deerfield the amount of such advance if it is ultimately determined that Employee is not entitled to be indemnified against such Losses pursuant to this Section 8(n). 

19

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above. 

	
EMPLOYEE 		 		
DEERFIELD CAPITAL MANAGEMENT LLC 	
	 	
	 	
	 	
	
/s/ Jonathan W. Trutter 		 		
By: 		 /s/
    Marvin Shrear
	
Jonathan W. Trutter 		 		
Name:  		Marvin
    Shrear
	 		 		
Title:  		CFO

EXHIBIT A

GENERAL RELEASE 

AND COVENANT NOT TO SUE

     TO ALL WHOM THESE PRESENTS SHALL COME OR MAY CONCERN, KNOW that:

     ___________________ (“Employee”),
on Employee’s own behalf and on behalf of Employee’s
descendants, dependents, heirs, executors and administrators and permitted assigns,
past and present, in consideration for the amounts payable and benefits to be
provided to Employee under that Employment Agreement dated as of _______________
, 2004 (the “Employment Agreement”) by and between Employee and Deerfield Capital Management LLC, a Delaware limited liability company (the
“Company”) and wholly-owned subsidiary of Deerfield & Company LLC, an Illinois limited liability company (“D&C”) does hereby covenant not to sue or pursue any litigation (or file any charge or otherwise correspond with any Federal, state or local administrative agency) against, and waives,
releases and discharges the Company, D&C, Triarc Companies, Inc. and their respective assigns, affiliates, subsidiaries, parents, predecessors and successors, and the past and present shareholders, employees, officers, directors, representatives
and agents or any of them (collectively, the “Company Group”), from any and all claims, demands, rights, judgments, defenses, actions, charges or causes of action
whatsoever, of any and every kind and description, whether known or unknown, accrued or not accrued, that Employee ever had, now has or shall or may have or assert as of the date of this General Release and Covenant Not to Sue against the Company
Group, including, without limiting the generality of the foregoing, any claims, demands, rights, judgments, defenses, actions, charges or causes of action related to employment or termination of employment or that arise out of or relate in any way
to the Age Discrimination in Employment Act of 1967 (“ADEA,” a law that prohibits discrimination on the basis of age), the National Labor Relations Act, the Civil
Rights Act of 1991, the Americans With Disabilities Act of 1990, Title VII of the Civil Rights Act of 1964, the Employee Retirement Income Security Act of 1974, the Family and Medical Leave Act, the Sarbanes-Oxley Act of 2002, all as amended, and
other Federal, state and local laws relating to discrimination on the basis of age, sex or other protected class, all claims under Federal, state or local laws for express or implied breach of contract, wrongful discharge, defamation, intentional
infliction of emotional distress, and any related claims for attorneys’ fees and costs; provided, however, that nothing herein shall release any member of the Company Group from any of its obligations to Employee under the Employment Agreement or any rights Employee may have to indemnification under any charter or by-laws (or similar
documents) of any member of the Company Group. In addition, nothing herein shall release any rights Employee may have pursuant to the D&C LLC Agreement (as that term is defined in the Employment Agreement). Employee further agrees that this
General Release and Covenant Not to Sue may be pleaded as a full defense to any action, suit or other proceeding covered by the terms hereof that is or may be initiated, prosecuted or maintained by Employee, Employee’s heirs or assigns.
Notwithstanding the foregoing, Employee understands and confirms that Employee is executing this General Release and Covenant Not to Sue voluntarily and knowingly, and this General Release and Covenant Not to Sue shall not affect Employee’s
right to claim otherwise under ADEA. In addition, Employee shall not be precluded by this General Release and Covenant Not to Sue from filing a charge with any relevant Federal, State or local 

administrative agency, but Employee agrees not to participate in any such administrative proceeding (other than any proceeding brought by the Equal Employment Opportunity Commission), and agrees to waive Employee’s
rights with respect to any monetary or other financial relief arising from any such administrative proceeding. 

     In furtherance of the agreements set forth above, Employee hereby expressly waives and relinquishes any and all rights under any applicable statute, doctrine or principle of law restricting the
right of any person to release claims that such person does not know or suspect to exist at the time of executing a release, which claims, if known, may have materially affected such person’s decision to give such a release. In connection with
such waiver and relinquishment, Employee acknowledges that Employee is aware that Employee may hereafter discover claims presently unknown or unsuspected, or facts in addition to or different from those that Employee now knows or believes to be
true, with respect to the matters released herein. Nevertheless, it is the intention of Employee to fully, finally and forever release all such matters, and all claims relating thereto, that now exist, may exist or theretofore have existed, as
specifically provided herein. The parties hereto acknowledge and agree that this waiver shall be an essential and material term of the release contained above. Nothing in this paragraph is intended to expand the scope of the release as specified
herein. 

     This General Release and Covenant Not to Sue shall be governed by and construed in accordance with the laws of the State of Illinois, applicable to agreements made and to be performed entirely
within such State. 

     To the extent that Employee is forty (40) years of age or older, this paragraph shall apply. Employee acknowledges that Employee has been offered a period of time of at least twenty-one (21)
days to consider whether to sign this General Release and Covenant Not to Sue, which Employee has waived, and the Company agrees that Employee may cancel this General Release and Covenant Not to Sue at any time during the seven (7) days following
the date on which this General Release and Covenant Not to Sue has been signed by all parties to this General Release and Covenant Not to Sue. In order to cancel or revoke this General Release and Covenant Not to Sue, Employee must deliver to the
General Counsel of the Company written notice stating that Employee is canceling or revoking this General Release and Covenant Not to Sue. If this General Release and Covenant Not to Sue is timely cancelled or revoked, none of the provisions of this
General Release and Covenant Not to Sue shall be effective or enforceable and the Company shall not be obligated to make the payments to Employee or to provide Employee with the other benefits described in the Employment Agreement and all contracts
and provisions modified, relinquished or rescinded hereunder shall be reinstated to the extent in effect immediately prior hereto. 

     Employee acknowledges and agrees that Employee has entered into this General Release and Covenant Not to Sue knowingly and willingly and has had ample opportunity to consider the terms and
provisions of this General Release and Covenant Not to Sue. 

     IN WITNESS WHEREOF, the parties hereto have caused this General Release and Covenant Not to
Sue to be executed on this _______ day of ______________, _____.

	 
	
[Employee] 	
	 	
	 	
	
DEERFIELD CAPITAL MANAGEMENT LLC 	
	 
	 	
	
By: 		 
	 	Name:  
	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}]]